Loading…
Aligos Therapeutics, Inc. is projected to decline to $4.37 by 2027, a -5% move from its current price of $4.60. ALGS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $4.41 | $4.60 | $4.80 | +0.07% |
| Aug 6 | $4.34 | $4.61 | $4.89 | +0.14% |
| Aug 7 | $4.28 | $4.61 | $4.96 | +0.20% |
| Aug 8 | $4.23 | $4.61 | $5.03 | +0.27% |
| Aug 9 | $4.19 | $4.62 | $5.08 | +0.34% |
| Aug 10 | $4.16 | $4.62 | $5.13 | +0.41% |
| Aug 11 | $4.13 | $4.62 | $5.18 | +0.48% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.13 | $4.62 | $5.18 | +0.48% |
| Week 2 | $3.96 | $4.64 | $5.45 | +0.95% |
| Week 3 | $3.83 | $4.67 | $5.68 | +1.43% |
| Week 4 | $3.74 | $4.69 | $5.88 | +1.91% |
| Week 5 | $3.65 | $4.71 | $6.07 | +2.40% |
| Week 6 | $3.58 | $4.73 | $6.25 | +2.89% |
| Week 7 | $3.52 | $4.76 | $6.42 | +3.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidates include ALG-055009, a small molecule THR-ß agonist in Phase 2a for metabolic dysfunction-associated steatohepatitis and obesity; pevifoscorvir sodium, a capsid assembly modulator in Phase 2 B; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial.
The company was incorporated in 2018 and is headquartered in South San Francisco, California. It has entered into license and research collaboration agreements with Emory University and Katholieke Universiteit Leuven, further linking its research with academic partners.
Aligos Therapeutics, Inc. (ALGS) is a healthcare stock currently priced at $4.08 per share, with a market capitalization of $25.25M and a rank of 4573. The stock sits in a highly speculative space given its clinical-stage focus and small market cap, which can translate into significant volatility.
The year-by-year forecast shows an evolving price path from near the current level toward higher levels later in the period. The average forecast progresses from $4.08 in 2026 to $14.32 in 2050, with intermediate steps such as $3.88 in 2027, $3.65 in 2028, and $4.03 in 2029 before rising again in the 2030s and beyond.
A major floor 49.2% below — a decisive break under it would weaken the trend.
The nearest floor, 11.3% below — buyers have tended to step in here.
The nearest ceiling, 47.2% above — a clean break opens room to run.
A major ceiling 90.0% above — clearing it would confirm fresh momentum.
Key ALGS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALGS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.23 | Buy | $4.32 | Buy |
| MA 10 | $4.58 | Buy | $4.60 | Sell |
| MA 20 | $5.38 | Sell | $4.99 | Sell |
| MA 50 | $5.40 | Sell | $5.47 | Sell |
| MA 100 | $6.16 | Sell | $6.09 | Sell |
| MA 200 | $7.39 | Sell | $7.23 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 32.38 | Neutral |
| Stoch RSI (14) | 16.45 | Buy |
| CCI (20) | -94.82 | Neutral |
| Williams %R (14) | -92.59 | Info |
| MACD (12,26,9) | -0.15 | Sell |
| ROC (12) | -26.69 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 7.41 | Buy |
| TRIX (15) | -0.60 | Sell |
| Awesome (5,34) | -1.18 | Sell |
| Ultimate (7,14,28) | 19.02 | Buy |
| Momentum (10) | -1.51 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 4.13 | Buy |
| ADX (14) | 23.60 | Sell |
| ATR (14) | 0.20 | Info |
Near term sentiment is BEARISH, with RSI14 at 30. The stock’s short-term momentum is weak, and the 50-day moving average sits at $5.62 while the 200-day moving average sits at $7.56. The current price is below the stated support level of $4.69 and could face additional pressure given the bearish setup.
The stock trades within a 30-day range of $3.11 to $5.36. This range highlights the tight near-term volatility, while the annualized volatility stands at 80%, underscoring the potential for rapid moves on news and trial updates.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.08 | $4.60 | $6.13 | 0% | Neutral | |
| $3.31 | $4.37 | $6.21 | -5% | Neutral | |
| $2.93 | $4.06 | $6.09 | -12% | Neutral | |
| $3.05 | $4.39 | $6.87 | -4% | Neutral | |
| $2.89 | $4.33 | $7.00 | -6% | Neutral | |
| $3.46 | $5.34 | $8.91 | +16% | Neutral | |
| $3.95 | $6.30 | $10.79 | +37% | Bullish | |
| $3.73 | $6.11 | $10.73 | +33% | Bullish | |
| $3.45 | $5.82 | $10.44 | +27% | Bullish | |
| $3.11 | $5.40 | $9.89 | +17% | Neutral | |
| $4.22 | $8.33 | $16.58 | +81% | Bullish | |
| $6.87 | $15.26 | $34.20 | +232% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $4.08 | $4.60 | $5.76 | +0.00% |
| September 2026 | $4.13 | $4.96 | $6.19 | +7.89% |
| October 2026 | $4.03 | $4.89 | $6.20 | -1.41% |
| November 2026 | $3.81 | $4.68 | $6.01 | -4.40% |
| December 2026 | $3.81 | $4.71 | $6.13 | +0.74% |
Click any year to see its month-by-month ALGS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ALGS could reach as high as $6.13, with a base case around $4.60 and support toward $4.08 — roughly 0% from $4.60. Price action looks broadly range-bound.
Expect ALGS to range from $3.31 to $6.21 through 2027. The $4.37 average target implies a -5% move from current prices. That is -5% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The ALGS price prediction for 2028 points to an average of $4.06 (low $2.93, high $6.09) — a potential decline of -12% on today's $4.60. Price action looks broadly range-bound.
In 2029, ALGS is projected to trade between $3.05 and $6.87, averaging $4.39 — a potential decline of -4% from today's $4.60. That is up +8% on the projected 2028 average. A consolidation phase looks the most probable path here.
Aligos Therapeutics, Inc.'s 2030 outlook centres on $4.33, within a $2.89 to $7.00 range. That is -2% versus the projected 2029 average. That marks a -6% change versus current levels. Price action looks broadly range-bound.
By 2031, ALGS could reach as high as $8.91, with a base case around $5.34 and support toward $3.46 — roughly +16% from $4.60. A consolidation phase looks the most probable path here.
Expect ALGS to range from $3.95 to $10.79 through 2032. The $6.30 average target implies a +37% move from current prices. That is up +18% on the projected 2031 average. Momentum favours further upside here.
The ALGS price prediction for 2033 points to an average of $6.11 (low $3.73, high $10.73) — a potential gain of +33% on today's $4.60. Buyers look set to stay in control over this stretch.
In 2034, ALGS is projected to trade between $3.45 and $10.44, averaging $5.82 — a potential gain of +27% from today's $4.60. That is -5% versus the projected 2033 average. Momentum favours further upside here.
Aligos Therapeutics, Inc.'s 2035 outlook centres on $5.40, within a $3.11 to $9.89 range. That is -7% versus the projected 2034 average. That marks a +17% change versus current levels. A consolidation phase looks the most probable path here.
By 2040, ALGS could reach as high as $16.58, with a base case around $8.33 and support toward $4.22 — roughly +81% from $4.60. Momentum favours further upside here.
Expect ALGS to range from $6.87 to $34.20 through 2050. The $15.26 average target implies a +232% move from current prices. That is up +83% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ALGS today (≈ 217.391304 ALGS) could be worth
$3,318.31
+$2,318.31 (+232%) by 2050 · US Dollar
Based on the average projected ALGS price of $15.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALGSwould be worth at today's price.
$1,000 invested in ALGS on Jul 31, 2025 (≈ 137.362633 ALGS) would be worth
$631.87
-$368.13 (-36.8%) today · 0.63× · US Dollar
Based on a ALGS entry price of $7.28 vs. today's $4.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.08 | $1,127.45 | +12.7% |
| 1 month ago | $5.45 | $844.04 | -15.6% |
| 3 months ago | $6.09 | $755.34 | -24.5% |
| 6 months ago | $7.95 | $578.62 | -42.1% |
| 1 year ago | $7.28 | $631.87 | -36.8% |
| All time (5.0y) ago | $405.75 | $11.34 | -98.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALGS forecast.
Our base-case forecast reaches $9.20 around 2050.
Implied market cap at $9.20: $49.57M
Over the multi-year horizon, the forecast shows a shift from near-term neutrality to longer-term bullish momentum. The 2030 average is $3.90 with a ROI of -4.4%, followed by a transition to stronger upside in the early 2030s and beyond. By 2032 the average climbs to $5.81 with a ROI of 42.4%, and by 2033 it is $5.45 with a ROI of 33.5%.
From 2032 onward the outlook turns increasingly bullish, with 2034 average $5.25 (ROI 28.6%), 2035 average $5.07 (ROI 24.3%), and 2040 average $7.69 (ROI 88.6%). The long-run forecast culminates in 2050 with an average of $14.32 and a max of $31.53, delivering a ROI of 250.9% under bullish conditions. The latest years carry bullish sentiment, contrasting with earlier neutral readings, reflecting a brighter longer-term outlook despite short-term headwinds.
Tap a question to reveal the answer.
The 2030 average is $3.90 with a ROI of -4.4% and a neutral sentiment. These are estimates and not guarantees.
Forecasts show a path from near-term neutral to longer-term bullish momentum, with 2032–2050 averages rising to $5.81 and $14.32 respectively and max values up to $31.53. ROI ranges up to 250.9% by 2050, but near-term sentiment is Neutral and there is notable volatility.
Yes, based on the forecast the max price reaches $15.09 in 2040 and $31.53 in 2050, with earlier years' max around $9.85 (2032) to $9.17 (2035). Reaching $10 appears possible by 2040 according to these projections.
$3.11 to $5.36.
Current price is $4.08 and market cap is $25.25M. The stock is ranked 4573.
Aligos Therapeutics, Inc. Community Discussion
0Share your Aligos Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.